|Other Names||HRAS-like suppressor 3, HRSL3, Adipose-specific phospholipase A2, AdPLA, Group XVI phospholipase A1/A2, H-rev 107 protein homolog, HRAS-like suppressor 1, HREV107-1, HREV107-3, Renal carcinoma antigen NY-REN-65, PLA2G16, HRASLS3, HREV107|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Exhibits PLA1/2 activity, catalyzing the calcium- independent hydrolysis of acyl groups in various phosphatidylcholines (PC) and phosphatidylethanolamine (PE). For most substrates, PLA1 activity is much higher than PLA2 activity. Specifically catalyzes the release of fatty acids from phospholipids in adipose tissue (By similarity). N- and O- acylation activity is hardly detectable. Might decrease protein phosphatase 2A (PP2A) activity.|
|Cellular Location||Cytoplasm. Cytoplasm, perinuclear region. Membrane; Single-pass membrane protein|
|Tissue Location||Widely expressed. low expression, if any, in hematopoietic cells and thymus. In testis, confined to round spermatids. Expressed in normal ovarian epithelial cells. Down- regulated in some ovarian carcinomas and testicular germ cell tumors.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PLA2G16 specifically catalyzes the release of fatty acids from phospholipids in adipose tissue. It also has a weak lysophospholipase activity (By similarity). Tumor suppressor that may be involved in interferon-dependent cell death.
Uyama, T., et al. Biochim. Biophys. Acta 1791(12):1114-1124(2009)Duncan, R.E., et al. J. Biol. Chem. 283(37):25428-25436(2008)Nazarenko, I., et al. J. Cell. Sci. 120 (PT 8), 1393-1404 (2007) Nazarenko, I., et al. Am. J. Pathol. 169(4):1427-1439(2006)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.